Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 442

1.

Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I.

Pardridge WM, Boado RJ, Giugliani R, Schmidt M.

BioDrugs. 2018 Feb 13. doi: 10.1007/s40259-018-0264-7. [Epub ahead of print]

PMID:
29442294
2.

Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.

Boado RJ, Lu JZ, Hui EK, Pardridge WM.

Mol Pharm. 2018 Feb 5;15(2):602-608. doi: 10.1021/acs.molpharmaceut.7b00958. Epub 2017 Dec 29.

PMID:
29251941
3.

Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.

Pardridge WM.

BioDrugs. 2017 Dec;31(6):503-519. doi: 10.1007/s40259-017-0248-z. Review.

PMID:
29067674
4.

Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.

Chang R, Knox J, Chang J, Derbedrossian A, Vasilevko V, Cribbs D, Boado RJ, Pardridge WM, Sumbria RK.

Mol Pharm. 2017 Jul 3;14(7):2340-2349. doi: 10.1021/acs.molpharmaceut.7b00200. Epub 2017 May 31.

PMID:
28514851
5.

Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein.

Boado RJ, Pardridge WM.

Mol Pharm. 2017 Apr 3;14(4):1271-1277. doi: 10.1021/acs.molpharmaceut.6b01166. Epub 2017 Mar 16.

PMID:
28279069
6.

Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.

Pardridge WM.

Expert Opin Biol Ther. 2016 Dec;16(12):1455-1468. Epub 2016 Sep 7. Review.

PMID:
27572805
7.

Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey.

Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Mol Pharm. 2016 Sep 6;13(9):3241-6. doi: 10.1021/acs.molpharmaceut.6b00456. Epub 2016 Aug 19.

PMID:
27513815
8.

CSF, blood-brain barrier, and brain drug delivery.

Pardridge WM.

Expert Opin Drug Deliv. 2016 Jul;13(7):963-75. doi: 10.1517/17425247.2016.1171315. Epub 2016 Apr 11. Review.

PMID:
27020469
9.

Insulin Receptor Antibody-α-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts.

Boado RJ, Lu JZ, Hui EK, Lin H, Pardridge WM.

Mol Pharm. 2016 Apr 4;13(4):1385-92. doi: 10.1021/acs.molpharmaceut.6b00037. Epub 2016 Mar 2.

PMID:
26910785
10.

Non-invasive gene targeting to the fetal brain after intravenous administration and transplacental transfer of plasmid DNA using PEGylated immunoliposomes.

Cornford EM, Hyman S, Cornford ME, Chytrova G, Rhee J, Suzuki T, Yamagata T, Yamakawa K, Penichet ML, Pardridge WM.

J Drug Target. 2016;24(1):58-67. doi: 10.3109/1061186X.2015.1055569. Epub 2015 Jul 2.

PMID:
26133964
11.

Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery.

Pardridge WM.

Expert Opin Ther Targets. 2015;19(8):1059-72. doi: 10.1517/14728222.2015.1042364. Epub 2015 May 2. Review.

PMID:
25936389
12.

Targeted delivery of protein and gene medicines through the blood-brain barrier.

Pardridge WM.

Clin Pharmacol Ther. 2015 Apr;97(4):347-61. doi: 10.1002/cpt.18. Epub 2014 Dec 15. Review.

PMID:
25669455
13.

Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.

Pardridge WM.

Expert Opin Drug Deliv. 2015 Feb;12(2):207-22. doi: 10.1517/17425247.2014.952627. Epub 2014 Aug 20. Review.

PMID:
25138991
14.

Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells.

Boado RJ, Lu JZ, Hui EK, Pardridge WM.

Mol Pharm. 2014 Aug 4;11(8):2928-34. doi: 10.1021/mp500258p. Epub 2014 Jun 26.

15.

Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.

Boado RJ, Ka-Wai Hui E, Zhiqiang Lu J, Pardridge WM.

Biotechnol Bioeng. 2014 Nov;111(11):2317-25. doi: 10.1002/bit.25289. Epub 2014 Aug 5.

16.

Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey.

Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM.

Bioconjug Chem. 2013 Oct 16;24(10):1741-9. doi: 10.1021/bc400319d. Epub 2013 Oct 3.

PMID:
24059813
17.
18.

Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins.

Sumbria RK, Boado RJ, Pardridge WM.

Brain Res. 2013 Apr 24;1507:91-6. doi: 10.1016/j.brainres.2013.02.022. Epub 2013 Feb 18.

PMID:
23428543
19.

Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice.

Sumbria RK, Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

Mol Pharm. 2013 Apr 1;10(4):1425-31. doi: 10.1021/mp400004a. Epub 2013 Feb 28.

20.

IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.

Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Bioconjug Chem. 2013 Jan 16;24(1):97-104. doi: 10.1021/bc3005123. Epub 2012 Dec 31.

21.

Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor.

Boado RJ, Lu JZ, Hui EK, Sumbria RK, Pardridge WM.

Biotechnol Bioeng. 2013 May;110(5):1456-65. doi: 10.1002/bit.24795. Epub 2012 Dec 25.

22.

Drug transport across the blood-brain barrier.

Pardridge WM.

J Cereb Blood Flow Metab. 2012 Nov;32(11):1959-72. doi: 10.1038/jcbfm.2012.126. Epub 2012 Aug 29. Review.

23.

Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.

Zhou QH, Boado RJ, Pardridge WM.

J Drug Target. 2012 Sep;20(8):715-9. doi: 10.3109/1061186X.2012.712132.

PMID:
22845843
24.

Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor.

Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Drug Metab Dispos. 2012 Oct;40(10):2021-5. doi: 10.1124/dmd.112.046375. Epub 2012 Jul 20.

25.

Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein.

Sumbria RK, Boado RJ, Pardridge WM.

J Cereb Blood Flow Metab. 2012 Oct;32(10):1933-8. doi: 10.1038/jcbfm.2012.97. Epub 2012 Jun 20.

26.

Imaging amyloid plaque in Alzheimer's disease brain with a biotinylated Aβ peptide radiopharmaceutical conjugated to an IgG-avidin fusion protein.

Sumbria RK, Boado RJ, Pardridge WM.

Bioconjug Chem. 2012 Jun 20;23(6):1318-21. doi: 10.1021/bc3001744. Epub 2012 Jun 6.

PMID:
22624578
27.

Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.

Pardridge WM, Boado RJ.

Methods Enzymol. 2012;503:269-92. doi: 10.1016/B978-0-12-396962-0.00011-2. Review.

PMID:
22230573
28.

The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier.

Boado RJ, Pardridge WM.

J Drug Deliv. 2011;2011:296151. doi: 10.1155/2011/296151. Epub 2011 Nov 16.

29.

Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse.

Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM.

Drug Metab Dispos. 2012 Feb;40(2):329-35. doi: 10.1124/dmd.111.042903. Epub 2011 Nov 7.

30.

Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.

Zhou QH, Sumbria R, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

J Pharmacol Exp Ther. 2011 Nov;339(2):618-23. doi: 10.1124/jpet.111.185876. Epub 2011 Aug 10.

31.

Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.

Zhou QH, Lu JZ, Hui EK, Boado RJ, Pardridge WM.

Bioconjug Chem. 2011 Aug 17;22(8):1611-8. doi: 10.1021/bc200174x. Epub 2011 Jul 6.

32.

Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.

Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM.

Mol Pharm. 2011 Aug 1;8(4):1342-50. doi: 10.1021/mp200136x. Epub 2011 Jun 17.

PMID:
21667973
33.

Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein.

Zhou QH, Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Drug Metab Dispos. 2011 Jul;39(7):1149-54. doi: 10.1124/dmd.111.038349. Epub 2011 Apr 18.

34.

Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein.

Lu JZ, Boado RJ, Hui EK, Zhou QH, Pardridge WM.

Biotechnol Bioeng. 2011 Aug;108(8):1954-64. doi: 10.1002/bit.23118. Epub 2011 Mar 15.

35.

Drug transport in brain via the cerebrospinal fluid.

Pardridge WM.

Fluids Barriers CNS. 2011 Jan 18;8(1):7. doi: 10.1186/2045-8118-8-7.

36.

Biologic TNFα-inhibitors that cross the human blood-brain barrier.

Pardridge WM.

Bioeng Bugs. 2010 Jul-Aug;1(4):231-4. doi: 10.4161/bbug.1.4.12105. Epub 2010 Apr 14.

37.

Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.

Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

Brain Res. 2011 Mar 25;1382:315-20. doi: 10.1016/j.brainres.2011.01.061. Epub 2011 Jan 26.

38.

Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.

Zhou QH, Fu A, Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Mol Pharm. 2011 Feb 7;8(1):280-5. doi: 10.1021/mp1003515. Epub 2010 Dec 21.

39.

Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.

Fu A, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

Brain Res. 2011 Jan 19;1369:203-7. doi: 10.1016/j.brainres.2010.10.097. Epub 2010 Oct 31.

PMID:
21047502
40.

Brain-penetrating tumor necrosis factor decoy receptor in the mouse.

Zhou QH, Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Drug Metab Dispos. 2011 Jan;39(1):71-6. doi: 10.1124/dmd.110.036012. Epub 2010 Sep 30.

41.

Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.

Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM.

Mol Pharm. 2010 Dec 6;7(6):2148-55. doi: 10.1021/mp1001763. Epub 2010 Oct 7.

PMID:
20860349
42.

Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein.

Fu A, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

Brain Res. 2010 Nov 11;1360:193-7. doi: 10.1016/j.brainres.2010.09.009. Epub 2010 Sep 9.

PMID:
20833153
43.

CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein.

Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Biotechnol Bioeng. 2011 Jan;108(1):186-96. doi: 10.1002/bit.22907.

PMID:
20803562
44.

Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier.

Fu A, Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM.

Brain Res. 2010 Sep 17;1352:208-13. doi: 10.1016/j.brainres.2010.06.059. Epub 2010 Jun 30.

45.

Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier.

Pardridge WM.

Cold Spring Harb Protoc. 2010 Apr;2010(4):pdb.prot5407. doi: 10.1101/pdb.prot5407.

PMID:
20360361
46.

Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse.

Boado RJ, Hui EK, Lu JZ, Pardridge WM.

J Pharmacol Exp Ther. 2010 Jun;333(3):961-9. doi: 10.1124/jpet.109.165092. Epub 2010 Mar 16.

47.

Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.

Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM.

J Biotechnol. 2010 Mar;146(1-2):84-91. doi: 10.1016/j.jbiotec.2010.01.011. Epub 2010 Jan 25.

48.

Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse.

Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM.

Drug Metab Dispos. 2010 Apr;38(4):566-72. doi: 10.1124/dmd.109.031534. Epub 2010 Jan 14.

49.

Biopharmaceutical drug targeting to the brain.

Pardridge WM.

J Drug Target. 2010 Apr;18(3):157-67. doi: 10.3109/10611860903548354. Review.

PMID:
20064077
50.

Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.

Lu JZ, Hui EK, Boado RJ, Pardridge WM.

Bioconjug Chem. 2010 Jan;21(1):151-6. doi: 10.1021/bc900382q.

PMID:
20000684

Supplemental Content

Loading ...
Support Center